As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer.
Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course.